Navigation Links
Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited

NEW YORK, May 20 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced that Richard Taney, President and Chief Executive Officer, provided an update on enrollment numbers in the Company's pivotal Phase III clinical trial today at a gathering of financial and healthcare industry leaders attending the Rodman & Renshaw 5th Annual Global Healthcare Conference.

Mr. Taney's comments updated patient recruitment levels for the Phase III clinical trial of the Company's Percutaneous Hepatic Perfusion (PHP) technology for inoperable cancers in the liver. Enrollment in this pivotal trial, which is treating patients with metastatic melanoma, now totals 32 patients which surpasses one-third of the 92 patients required to complete enrollment of the trial. This represents an acceleration in patient enrollment in this NCI-led multi center trial, and occurs before accrual has begun at the first additional trial site which is the University of Maryland Medical Center.

Although the company is prevented from commenting on results from the randomized Phase III trial, Mr. Taney was able to update the audience on the parallel Phase II trial for patients with metastatic melanoma in the liver who had previously received surgical isolated regional therapy and are therefore ineligible for admission to the pivotal Phase III study. All five of the patients treated in this arm to date have shown responses to PHP and four of the five (80%) have shown objective tumor responses of 30% or greater reduction in tumor size.

Mr. Taney also discussed the metastatic neuroendocrine arm of Delcath's ongoing Phase II trial. This study was the subject of a well-attended presentation during the American Hepato Pancreato Biliary Association Annual Meeting in March of this year. At that meeting, NCI investigators reported a 79% overall response rate in the 23 evaluable patients, including two complete responses. In addition to reporting an unprecedented rate of response in this patient group, the median hepatic progression free survival was reported to be 39 months.

The presentation was webcast live and will be available for ninety days and accessible at .

About Delcath Systems, Inc.

Delcath Systems is a developmental stage company testing its percutaneous perfusion technology for the isolated delivery of high doses of therapeutic and chemotherapeutic agents. The Delcath System is currently being tested in Phase III and Phase II clinical trials for the treatment of hepatocellular carcinoma and metastatic tumors in the liver, including melanomas, neuroendocrine tumors and adenocarcinomas. The Company's intellectual property portfolio currently consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
3. Diamyd Updates Gene Therapy Program and Outlines Plans for Phase I Clinical Trial for Treatment of Cancer Pain
4. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
5. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
6. Alliance Pharmaceutical Corp. Updates Oxygent(TM) Clinical Development Plan
7. Imaging Diagnostic Systems Updates PMA Filing Status for the New CT Laser Breast Imaging System
8. BioCryst Updates Peramivir Clinical Development Plan
9. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
10. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
11. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
Post Your Comments:
(Date:11/26/2015)... November 26, 2015 ... the "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Country Segment Forecasts, ... their offering. --> ) ... "2016 Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , Nov. 26, 2015 Research and Markets ... "Advanced Wound Care Market by Type (Dressings, Therapy ... User (In-Patient Facility, Out-Patient Facility), and Geography - Global ... --> --> The ... definition and forecast of the global advanced wound care ...
(Date:11/26/2015)... PUNE, India , November 26, ... --> --> ... Research Report" and "Investigation Report on ... 2019 and 2021 forecasts data and ... library. . ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... According to an ... changing the way that they are handling security in light of the recent terrorist ... presence in an attempt to stop an attack from reaching U.S. soil. Especially around ...
(Date:11/27/2015)... ... 27, 2015 , ... "When I was traveling, I was ... N.J. "Many people catch diseases simply from sitting on such dirty toilet seats. ... from germs." , He developed the patent-pending QUDRATECS to eliminate the need to ...
(Date:11/27/2015)... ... ... the No.1 Herpes-only dating community in the world, revealed that over 50% of its members ... billion people under the age of 50 – or 67% of the population - are ... of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, Co-Founder ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
(Date:11/27/2015)... ... November 27, 2015 , ... Dr. Thomas Dunlap ... Inc. and Dr. Tucker Bierbaum with Emergency Medicine at St., Joseph Health ... both STEMI and Sepsis conditions present in similar ways and require time-critical intervention to ...
Breaking Medicine News(10 mins):